James Burton, MD

Professional Titles

• Medical Director of Liver Transplantation
• Section Head of Hepatology

Publications

• Burton JR, Klarquist J, Im KM, Belle SH, et al. Stronger baseline HCV-specific immunity is associated with a higher likelihood of a sustained virological response to combination antiviral therapy of chronic hepatitis C. Accepted as poster of distinction at DDW, May 21, 2006
• Burton JR, Rosen HR. Treatment of HCV recurrence: Do the pre-transplant treatment rules apply? Liver Transpl 2006; (in press)
• Burton JR, Rosen HR. Recurrent Disease Following Liver Transplantation. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Disease of the Liver. 10th ed. New York: Lippincott Williams & Wilkins; 2006: (in press)
• Burton JR, Rosen HR. Liver retransplantation for hepatitis C virus recurrence: A survey of liver transplant programs in the United States. Clin Gastroenterol Hepatol 2005;3:700-704.
• Hugo R. Rosen, Scott J. Weston, KyungAh Im, Huiying Yang, James R. Burton, et al. Selective decrease in hepatitis C virus-specific immunity among African Americans and Outcome of Antiviral Therapy.
• McCashland T, Lyden E, Adams L, McGuire B, Burton JR and the US Retransplant Study Group. Is retransplantation for HCV a bad idea? Results of a US multicenter retransplant study. Oral presentation at International Liver Transplant Society 11th Annual International Congress, Los Angeles, July 2005.
• Burton JR, Klarquist, J, Im KA, Belle SH, Rosen HR for Virahep-C Study Group. Stronger baseline HCV-specific immunity is associated with a higher likelihood of a sustained virological response to combination antiviral therapy of chronic hepatitis C (abstract; presented as poster at DDW, Los Angeles, May 2006)
• Burton JR, Rosen HR. Treatment of HCV recurrence: Do the pretransplant rules apply? Liver Transpl 2006;12:1044-8.
• Burton JR, Rosen HR. Diagnosis and management of allograft failure. Clin Liver Dis. 2006;10:407-35.
• Burton JR, Klarquist J, Im K, et al. Contraction of HCV-specific CD4+ T cell responses in patients undergoing antiviral therapy irrespective of race and virologic outcome. Hepatology 2006 (Suppl);44:327A. Poster presentation at 2006 AASLD Meeting, Boston, MA.
• Burton JR, Golden-Mason L, Im K, et al. Prospective analysis of CD4+CD25HiFoxP3+ regulatory T cells in chronic HCV patients undergoing antiviral therapy. Hepatology 2006 (Suppl);44:314A. Poster presentation at 2006 AASLD meeting, Boston, MA.
• Burton JR, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: The great conundrum. Liver Transpl 2006;12:S38-S47.
• Golden-Mason L, Burton JR, Castelblanco N, et al. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology 2006;44:1098-1109.
• Rosen HR, Burton JR. Recurrent Disease Following Liver Transplantation. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Disease of the Liver. 10th ed. New York: Lippincott Williams & Wilkins; 2007: 1525-1544.
• Burton JR, Suthat L, Lapidus J, Giannini E, Chalasani N, Zaman A. Validation of a multivariate model predicts presence and size of varices. J Clin Gastroenterol 2007; (in press).
• McCashland T, Lyden E, Adams L, McGuire B, Burton JR and the US Retransplant Study Group. Is retransplantation for HCV a bad idea? Results of a US multicenter retransplant study. Liver Transplantation 2007 (in press).
• Burton JR, Golden-Mason L, Rosen HR. Immunopathogenesis and Outcomes of Recurrent Hepatitis C. In: Gershwin ME, Vierling JM, Manns MP, eds. Liver Immunology: Principles and Practice. 1st ed. Totowa, New Jersey: Humana Press; 2007:459-470.
• Burton JR, Suthat L, Lapidus J, Giannini E, Chalasani N, Zaman A. Validation of a multivariate model predicts presence and size of varices. J Clin Gastroenterol 2007;41:609-15.
• Arjal RR, Burton JR, Villamil F, Rosen HR. Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther 2007;26:127-40.
• Rosen HR, Weston SJ, Im K, Yang, Burton JR, Erlich H, et al. Selective decrease in hepatitis C virus-specific immunity amont African Americans and outcome of antiviral therapy. Hepatology 2007;46:350-8.
• McCashland T, Lyden E, Adams L, McGuire B, Burton JR and the US Retransplant Study Group. Is retransplantation for HCV a bad idea? Results of a US multicenter retransplant study. Liver Transpl 2007;13:1246-53.
• Smyk-Pearson S, Golden-Mason L, Klarquist J, Burton JR, Tester IA, Wang CC, Culbertson N, Vandenbark AA, Rosen HR. Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis 2008;197:46-57.
• Yen R, Burton Jr JR, Shah R. Severe Recurrent Hepatitis C Following Liver Transplantation is Associated with Higher Rates of Anastomotic Strictures. Poster presentation at DDW May 2009.
• Fortune B, Rosen HR, Burton Jr JR. Management of HCV Infection and Liver Transplantation. In: McDonald J, Burroughs A, Feagan B, and Fennerty MB Eds. Evidence-Based Gastroenterology and Hepatology, 3rd Edition. BMJ Books, London, In Press.
• Burton Jr JR, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, Terrault NA, Rosen HR. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol 2008 Sep;49:329-338.
• Fortune BE, Rosen HR, Burton JR. Management of HCV Infection and Liver Transplantation. In: McDonald, Burroughs, Feagan and Fennerty Eds. Evidence-Based Gastroenterology and Hepatology (3rd Ed). Wiley-Blackwell, Oxford. (In press)
• Burton JR, Rosen HR, Martin P. Biological Principles and Clinical Issues Underlying Liver Transplantation for Virus-Induced End-Stage Liver Disease. In: Arias, Alter, Boyer, Cohen, Fausto, Shafritz and Wolkoff. Eds. The Liver: Biology and Pathobiology (5th Ed). John Wiley & Sons, Ltd. 2009.
• Burton JR, Everson GT. NS5B-Polymerase Inhibitors. Clin Liv Disease 2009;13:453-65.
• Fortune BE, Rosen HR, Burton JR. Management of HCV Infection and Liver Transplantation. In: McDonald, Burroughs, Feagan and Fennerty Eds. Evidence-Based Gastroenterology and Hepatology (3rd Ed). Wiley-Blackwell, Oxford 2010.
• Berman K, Tandra S, Forssell K, Vuppalanch R, Burton JR, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol 2011;9:254-9.
• Benson AB, Burton JR, Austin GL, Biggins SW, Zimmerman MA, et al. Differential effects of plasm and red blood cell transfusion on acute lung injury and infection risk following liver transplantation. Liver Transpl 2011;17:149-58.
• Antiviral Therapy for Recurrent HCV after Simultaneous Liver-Kidney Transplantation; A Case Series. Kirkland, H, Burton JR. Oral presentation at Young Investigator's Forum, Breckenridge, CO, March 3, 2011.
• Initial Experience with Telaprevir for Treating Hepatitis C in Liver Recipients: Virologic Response, Safety, and Tolerability. Late Breaking Abstract. American Transplant Congress, June 6, 2012.
• Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and managemtn of drug interactions with boceprevir and telaprevir. Hepatology 2012 [Epub ahead of print]
• Harry BL, Smith ML, Burton JR, Dasari A, Eckhardt SG, Diamond JR. Medullary thyroid cancer and pseudocirrhosis: case report and literature review. Curr Oncol 2012;19:e36-41.
• Burton JR. Timing of Referral for Liver Transplantation. In: Zaman A Ed. Managing the Complications of Cirrhosis: A Practical Approach. (1st Ed). Slack Inc., 2012.
• Fortune BE, Martinez-Camacho A, Burton JR. Should living donor liver transplantation be an option for patients with hepatocellular carcinoma beyond Milan criteria? In: Jensen DM Ed. Controversies in Hepatology: The Experts Analyze Both Sides. (1st Ed). Slack Inc., 2011.
• Burton JR, Everson GT. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis 2013;17:73-91.
• Hammond KP, Wolfe P, Burton JR, Predhomme JA, Ellis CM, Ray ML, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr 2013;62:67-73.
• Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012;55:1620-8.
• Harry BL, Smith ML, Burton JR, Dasari A, Eckhardt SG, Diamond JR. Medullary thyroid cancer and pseudocirrhosis: case report and literature review. Curr Oncol 2012;19:e36-41.
• Burton JR. Timing of Referral for Liver Transplantation. In: Zaman A Ed. Managing the Complications of Cirrhosis: A Practical Approach. (1st Ed). Slack Inc., 2012.
• Murad DS, Kim WR, Harnois DM, Douglas DD, Burton JR, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012;143:88-98.
• Burton JR, O’Leary JG, Verna EC, Lai JC, Everson GT, Trotter JF, et al. A multicenter study of preotease inhibitor-triple therapy in HCV-infected liver transplant recipients: Report from the CRUSH-C group. Hepatology 2012;56 (Suppl): 211. Presented at Presidential Plenary: Viral Hepatitis at AASLD 2012, Boston, MA, November 13, 2012.
• Burton, JR, Everson GT. Initial Experience with Telaprevir for Treating Hepatitis C in Liver Recipients: Virologic Response, Safety, and Tolerability. Late Breaking Abstract, Oral Presentation. American Transplant Congress, Boston, MA, June 6, 2012.
• Fortune BE, Sprague DR, Chascsa DM, Kirkland H, Forman LM, Biggins SW, and Burton, JR.. Incidence of early rejection between liver transplant recipients with related versus unrelated donor organs. Poster Presentation. Digestive Diseases Weekly 2012. San Diego, CA. May 19-22, 2012.
• Kiser JJ, Burton JR Jr, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):596-606. PubMed PMID: 23817323
• Biggins SW, Trotter J, Gralla J, Burton JR Jr, Bambha KM, Dodge J, Brocato M, Cheng L, McQueen M, Forman L, Chang M, Kam I, Everson G, Spritz RA, Klintmalm G, Rosen HR. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol. 2013 May;58(5):969-76. PubMed PMID: 23333445
• Burton JR Jr, Everson GT. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis. 2013 Feb;17(1):73-91. PubMed PMID: 23177284
• Burton JR Jr, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, Terrault NA. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014 Sep;61(3):508-14. PubMed PMID: 24801415
• Ladner DP, Dew MA, Forney S, Gillespie BW, Brown RS Jr, Merion RM, Freise CE, Hayashi PH, Hong JC, Ashworth A, Berg CL, Burton JR Jr, Shaked A, Butt Z. Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL). J Hepatol. 2015 Feb;62(2):346-53. PubMed PMID: 25195558
• Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, Gordon F, Levitsky J, Terrault NA, Burton JR Jr, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18;371(25):2375-82. PubMed PMID: 25386767
• Hammond KP, Wolfe P, Burton JR Jr, Predhomme JA, Ellis CM, Ray ML, Bushman LR, Kiser JJ. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):67-73. PubMed PMID: 23075915
• Moorehead KJ, Burton JR Jr, Everson GT, Zheng JH, Kerr BJ, Bushman LR, Wang M, Ju C, Nydam T, Kiser JJ. Intrahepatic antiviral quantification in a patient undergoing orthotopic cadaveric liver transplantation. J Antimicrob Chemother. 2015 Jan;70(1):315-7. PubMed PMID: 25213274
• O'Leary JG, Fontana RJ, Brown K, Burton JR Jr, Firpi-Morell R, Muir A, O'Brien C, Rabinovitz M, Reddy R, Ryan R, Shprecher A, Villadiego S, Prabhakar A, Brown RS Jr. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transpl Int. 2017 Feb;30(2):196-208. PubMed PMID: 27896858
• Dew MA, DiMartini AF, Ladner DP, Simpson MA, Pomfret EA, Gillespie BW, Merion RM, Zee J, Smith AR, Holtzman S, Sherker AH, Weinrieb R, Fisher RA, Emond JC, Freise CE, Burton JR Jr, Butt Z. Psychosocial Outcomes 3 to 10 Years After Donation in the Adult to Adult Living Donor Liver Transplantation Cohort Study. Transplantation. 2016 Jun;100(6):1257-69. PubMed PMID: 27152918
• Wilkey BJ, Hanson R, Reece TB, Forman L, Burton JR Jr, Messenger JC, Kim MS, Cleveland JC Jr, Fiegel MJ, Nydam TL, Mandell MS. Transfemoral Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease in Child's Class C Liver Disease Prior to Orthotopic Liver Transplantation: A Case Report. Semin Cardiothorac Vasc Anesth. 2016 Jun;20(2):158-62. PubMed PMID: 26620139
• Brown RS Jr, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR Jr, Stravitz RT, Durand C, Di Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Fried MW, Terrault NA. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016 Jan;22(1):24-33. PubMed PMID: 26519873
• MacBrayne CE, Castillo-Mancilla J, Burton JR Jr, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother. 2018 Jan 1;73(1):156-159. PubMed PMID: 29029135
• Kalra A, Burton JR Jr, Forman LM. Pro: Steroids Can Be Withdrawn After Transplant in Recipients With Autoimmune Hepatitis. Liver Transpl. 2018 Aug;24(8):1109-1112. PubMed PMID: 29923302
• Rice J, Dodge JL, Bambha KM, Bajaj JS, Reddy KR, Gralla J, Ganapathy D, Mitrani R, Reuter B, Palecki J, Acharya C, Shaw J, Burton JR, Biggins SW. Neutrophil-to-Lymphocyte Ratio Associates Independently With Mortality in Hospitalized Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2018 Nov;16(11):1786-1791.e1. PubMed PMID: 29705264
• Dew MA, Butt Z, Liu Q, Simpson MA, Zee J, Ladner DP, Holtzman S, Smith AR, Pomfret EA, Merion RM, Gillespie BW, Sherker AH, Fisher RA, Olthoff KM, Burton JR Jr, Terrault NA, Fox AN, DiMartini AF. Prevalence and Predictors of Patient-Reported Long-term Mental and Physical Health After Donation in the Adult-to-Adult Living-Donor Liver Transplantation Cohort Study. Transplantation. 2018 Jan;102(1):105-118. PubMed PMID: 28885494
• MacBrayne CE, Castillo-Mancilla J, Burton JR Jr, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother. 2018 Jan 1;73(1):156-159. PubMed PMID: 29029135
• Dew MA, Butt Z, Liu Q, Simpson MA, Zee J, Ladner DP, Holtzman S, Smith AR, Pomfret EA, Merion RM, Gillespie BW, Sherker AH, Fisher RA, Olthoff KM, Burton JR Jr, Terrault NA, Fox AN, DiMartini AF. Prevalence and Predictors of Patient-Reported Long-term Mental and Physical Health After Donation in the Adult-to-Adult Living-Donor Liver Transplantation Cohort Study. Transplantation. 2018 Jan;102(1):105-118. PubMed PMID: 28885494
• O'Leary JG, Fontana RJ, Brown K, Burton JR Jr, Firpi-Morell R, Muir A, O'Brien C, Rabinovitz M, Reddy R, Ryan R, Shprecher A, Villadiego S, Prabhakar A, Brown RS Jr. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transpl Int. 2017 Feb;30(2):196-208. PubMed PMID: 27896858
• Burton JR Jr, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Liver and Kidney Recipient Selection of HCV-Viremic Donors - Meeting Consensus Report from the 2019 Controversies in Transplantation. Transplantation. 2019 Oct 18. [Epub ahead of print] PubMed PMID: 31634329
• Hughes DL, Rice JD, Burton JR, Jin Y, Peterson RA, Ambardekar AV, Pomposelli JJ, Pomfret EA, Kriss MS. Presence of any degree of coronary artery disease among liver transplant candidates is associated with increased rate of post-transplant major adverse cardiac events. Clin Transplant. 2020 Nov;34(11):e14077. PubMed PMID: 32939833
• Burton JR Jr, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. Transplantation. 2020 Mar;104(3):476-481. PubMed PMID: 31634329
• Yoeli D, Jackson WE, Adams MA, Wachs ME, Sundaram SS, Sater A, Cisek JR, Choudhury RA, Nydam TL, Pomposelli JJ, Conzen KD, Kriss MS, Burton JR Jr, Pomfret EA. Challenging the Traditional Paradigm of Supply and Demand in Pediatric Liver Transplantation Through Nondirected Living Donation: A Case Series. Liver Transpl. 2021 Oct;27(10):1392-1400. PubMed PMID: 34048131
• Burton JR Jr, Helmke S, Lauriski S, Kittelson J, Everson GT. The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology. Transl Res. 2021 Jul;233:5-15. PubMed PMID: 33400995
• Jackson WE, Kriss MS, Burton JR Jr, Nydam TL, Conzen KD, Pomposelli JJ, Pomfret EA. Reply to "Living liver donation in previous kidney donors: A single-center experience". Am J Transplant. 2021 Jan;21(1):435-437. PubMed PMID: 32558135
• Jonica ER, Han S, Burton JR, Pomposelli JJ, Shah RJ. Choledocho-duodenostomy is associated with fewer post-transplant biliary complications compared to Roux-en-Y in primary sclerosing cholangitis patients. Clin Transpl 2022;May;36(5):e14597.
• Hunter BM, Bababekov YJ, Pomposelli JJ, Adams MA, Crouch C, Yoeli D, Choudhury RA, Ferrell T, Burton JR, Pompret EA, Nydam TL. The vexing triad of obesity, alcohol and coagulopathy predicts the need for multiple operations in liver transplantation. Am J Surg 2022;224;69-74.
• Burton JR Jr. The Loss of a Great One. Liver Transplantation 2022;28(4):728-29.
• Saben JL, Kaplan B, Burton JR Jr, Cooper JE, Pomposelli JJ, Schold JD, Pomfret EA. Highlights From Controversies in Transplantation 2023 Conference. Transplantation. 2023 Jun 14. [Epub ahead of print] PubMed PMID: 37314449
• Moore HB, Bababekov YJ, Pomposelli JJ, Adams MA, Crouch C, Yoeli D, Choudhury RA, Ferrell T, Burton JR, Pomfret EA, Nydam TL. The vexing triad of obesity, alcohol, and coagulopathy predicts the need for multiple operations in liver transplantation. Am J Surg. 2022 Jul;224(1 Pt A):69-74. PubMed PMID: 35227491
• McRae MP, Helmke SM, Burton JR Jr, Everson GT. Compartmental model describing the physiological basis for the HepQuant SHUNT test. Transl Res. 2023 Feb;252:53-63. PubMed PMID: 35948199
• Schold JD, Mohan S, Jackson WE, Stites E, Burton JR, Bababekov YJ, Saben JL, Pomposelli JJ, Pomfret EA, Kaplan B. Differential in Kidney Graft Years Based on Solitary Kidney, Simultaneous Liver-Kidney, and Kidney after Liver Transplants. Clin J Am Soc Nephrol. 2023 Nov 14. [Epub ahead of print] PubMed PMID: 37962880

Practice Locations

UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

UCHealth Hepatology Clinic - Anschutz Medical Campus
1635 Aurora Ct
7th Floor
Aurora, CO 80045
720-848-2280

Hospital Affiliation

• University of Colorado Hospital

Specialty Information

Specialties

• Internal Medicine, Board Certification (2000, 2010)
• Gastroenterology, Board Certification (2004, 2014)
• Transplant Hepatology, Board Certification (2006, 2016)

Conditions & Treatments

• Digestive System - Hepatology (Liver Disorders)
• Digestive System
• Surgery
• Surgery - Liver Transplant Surgery
• Surgery - Living Liver Donation